EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The antimycobacterial and healing effect of sorafenib through pro-apoptotic and immunomodulatory activities

Raju S Rajmani iD, Nidhi Rani, Avadhesha Surolia iD

Microbiology Spectrum · 03.03.2026 · 14 (3)

DOI: 10.1128/spectrum.01657-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 03.03.2026. Verfasst von Raju S Rajmani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India. Hauptthemen laut MEDLINE: Sorafenib, Mycobacterium tuberculosis, Apoptosis, Antitubercular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis is caused by the bacterium Mycobacterium tuberculosis (Mtb ). Emergence of drug resistance in Mtb requires continuous enrichment of anti-tubercular medication. Inclusion of host-directed therapies holds considerable promise in this context. Sorafenib (SRB) is a multi-kinase inhibitor targeting VEGF receptor kinase, Raf, MEK, and extracellular signal-regulated kinase (ERK) signaling cascade to treat several types of cancer, including hepatocellular carcinoma. We have previously established that SRB allosterically inhibits ornithine acetyltransferase (MtArgJ), an essential enzyme in the arginine biosynthesis pathway of Mtb , thereby limiting bacterial growth in culture at a minimum inhibitory concentration of 10 µg/mL. The current work focuses on how SRB at the dose of 30 mg/kg body wt inhibits the pathogenicity and survival of bacteria in a preclinical mouse model of tuberculosis by inducing pro-apoptotic and immunomodulatory mechanisms in the host. We observed that SRB treatment promotes apoptosis in Mtb -infected and -uninfected THP-1 cells, human monocyte-derived macrophages. Concomitantly, SRB treatment reduces infection-associated necrosis in the Mtb -infected THP-1 cells. We further noted the upregulated expression of pro-apoptotic proteins during SRB treatment in preclinical mouse models. In addition, we investigated the expression of pro- and anti-inflammatory cytokines and immunomodulation in lung tissues treated with SRB. Interestingly, SRB treatment increased the number of arginase 1-positive macrophages, which are reckoned to enhance tissue healing. In conclusion, our research discloses that SRB is helpful in both lowering the tubercular burden and accelerating recovery of damaged tissue by harnessing the host immune response. IMPORTANCE Host-directed therapies hold considerable promise for treating drug-resistant Mycobacterium tuberculosis ( Mtb ). In this context, the induction of apoptotic and immunomodulatory responses in the host by sorafenib (SRB) is demonstrated here to compromise the survival and pathogenic potential of Mtb in a preclinical mouse model of TB and in Mtb -infected and -uninfected THP-1 cells. Concurrently, the infection-associated necrosis in the Mtb -infected THP-1 cells is also reduced. Furthermore, arginase 1-positive macrophages, which are known to enhance tissue healing, are increased in SRB-treated groups. Thus, SRB treatment not only lowers the tubercular load but also aids in healing damaged tissues by leveraging the host immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibMycobacterium tuberculosisApoptosisAntitubercular AgentsTuberculosisAnimalsHumansMiceMacrophagesHost-Directed TherapyTHP-1 CellsDisease Models, AnimalFemale

Stichwörter der Autor:innen

Mycobacterium tuberculosis (Mtb)apoptosisimmunomodulationnecrosissorafenib (SRB)

Substanzen

SorafenibAntitubercular Agents

Autor:innen und Institutionen

  • Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India.
  • Dr. Reddy's Institute of Life Sciences, Hyderabad, India.

ORCID-Profile: Raju S Rajmani, Avadhesha Surolia

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India

Zitieren

APA

Rajmani, R. S., Rani, N., & Surolia, A. (2026). The antimycobacterial and healing effect of sorafenib through pro-apoptotic and immunomodulatory activities. Microbiology Spectrum, 14(3). https://doi.org/10.1128/spectrum.01657-25

Vancouver

Rajmani RS, Rani N, Surolia A. The antimycobacterial and healing effect of sorafenib through pro-apoptotic and immunomodulatory activities. Microbiology Spectrum. 2026;14(3). doi:10.1128/spectrum.01657-25

BibTeX
@article{Rajmani2026,
  author = {Rajmani, Raju S and Rani, Nidhi and Surolia, Avadhesha},
  title = {The antimycobacterial and healing effect of sorafenib through pro-apoptotic and immunomodulatory activities},
  journal = {Microbiology Spectrum},
  year = {2026},
  volume = {14},
  number = {3},
  doi = {10.1128/spectrum.01657-25}
}
Kostenlos starten →